← Back to Search

Ketamine for Dissociative Symptoms

Phase 1

Recruiting

Led By Karl Deisseroth, MD, PhD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age >18 years old.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 week

Awards & highlights

Study Summary

This trial will investigate how ketamine causes dissociative symptoms by looking at how it affects the brain.

Who is the study for?

This trial is for adults over 18 with epilepsy who are in the Stanford Epilepsy Monitoring Unit. It's not suitable for those who can't communicate in English, are pregnant or nursing, have had bad reactions to ketamine before, or have a history of psychotic or bipolar disorders.Check my eligibility

What is being tested?

The study focuses on understanding how ketamine may cause dissociative symptoms among epilepsy patients. Participants will receive ketamine under controlled conditions while their responses and experiences are closely monitored.See study design

What are the potential side effects?

Ketamine can lead to side effects such as feeling disconnected from reality (dissociation), changes in perception, confusion, agitation, drowsiness, increased blood pressure and heart rate.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 week

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 week

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 week for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale)

Trial Design

1Treatment groups

Experimental Treatment

Group I: KetamineExperimental Treatment1 Intervention

Study participants will receive 0.5mg/kg of ketamine - one single infusion

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ketamine

FDA approved

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,395 Previous Clinical Trials

17,341,335 Total Patients Enrolled

16 Trials studying Epilepsy

1,238 Patients Enrolled for Epilepsy

Karl Deisseroth, MD, PhD1.01 ReviewsPrincipal Investigator - Stanford University

Stanford University

1 Previous Clinical Trials

120 Total Patients Enrolled

1Patient Review

I was very uncomfortable around him. He was dismissive of my concerns about side effects and just increased the dosage. He spoke to me in a condescending way and made personal and sexual accusations. I would not recommend him to anyone.

Media Library

Ketamine Clinical Trial Eligibility Overview. Trial Name: NCT04861051 — Phase 1

Epilepsy Research Study Groups: Ketamine

Epilepsy Clinical Trial 2023: Ketamine Highlights & Side Effects. Trial Name: NCT04861051 — Phase 1

Ketamine 2023 Treatment Timeline for Medical Study. Trial Name: NCT04861051 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential hazards does this treatment pose to individuals?

"Our team at Power ranks the safety of this medical intervention as a 1, considering it is only in Phase 1. This indicates that there are limited studies to back its efficacy and safety."

Answered by AI

How many participants are engaged in this experiment?

"Indeed, the information available on clinicaltrials.gov affirms that enrollment is ongoing for this medical research project. The initial posting was made on July 26th 2021 and the details were most recently updated on October 25th 2022. A total of 20 participants are required to be recruited from one site only."

Answered by AI

Can individuals still join this experiment?

"Correct. According to clinicaltrials.gov, this medical investigation is currently open for participants; the initial posting date was July 26th 2021 and it underwent a recent modification on October 25th 2022. Currently, 1 site requires 20 individuals in order to start the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Understanding Ketamine's Dissociative Effects (KD Study)

Karl Deisseroth 2021. "Understanding Ketamine's Dissociative Effects (KD Study)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04861051.

All > Lgs Foundation > Epilepsy